Compare TGNA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGNA | VRDN |
|---|---|---|
| Founded | 1906 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | N/A | N/A |
| Metric | TGNA | VRDN |
|---|---|---|
| Price | $18.91 | $31.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $20.00 | ★ $41.17 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $2,876,414,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,080.80 |
| Revenue Next Year | $11.10 | $3.26 |
| P/E Ratio | $8.98 | ★ N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $14.87 | $9.90 |
| 52 Week High | $21.35 | $34.29 |
| Indicator | TGNA | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 47.48 |
| Support Level | $18.80 | $31.26 |
| Resistance Level | $19.00 | $34.20 |
| Average True Range (ATR) | 0.23 | 1.36 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 26.34 | 21.73 |
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).